ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Short Sellers Circle CoreWeave, Flee Chewy

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Short sellers added to positions in CoreWeave this week. Its short interest as a percentage of free float climbed to 24.8%, up from 21.2% seven days ago. That 3.6 percentage point jump is one of the biggest moves among mid-to-large US names over the past week.

BKV Corporation also drew fresh shorts. Its SI % FF rose to 38.6%, up nearly 4 points in seven days. Braveheart Bio (BRVE) sits at 39.1% of free float shorted and saw a 2.2 point increase. Its ORTEX short score stands at 85, signalling high bearish pressure.

On the other side, Chewy saw a notable retreat in short positioning. SI % FF dropped to 86.7% from 91.2% last week, a 4.5 point fall. Bears are trimming despite the stock remaining one of the most shorted names in the US market. Medtronic saw an even steeper relative unwind, falling 3.4 points to 3.5%.

Lucid Group stays deeply in bear territory at 64.3% of float shorted with 14.9 days to cover. Availability of shares to borrow is near zero, which raises squeeze risk if sentiment shifts.

EverCommerce carries the highest ORTEX short score among stocks above $1bn market cap, hitting 96 out of 100. Its cost to borrow is elevated at 97% APR and availability is just 7.5%.

Wolfspeed remains heavily shorted at 85.5% of free float with nearly 10 days to cover, as semiconductor bears hold firm on the chip-maker's mounting losses.

Stocks in this article

How this article was generated

Generated
23 Oct 2026, 20:02
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationAlt DataIndex Rebalance

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.